114 related articles for article (PubMed ID: 19637820)
1. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.
Cashen AF; Dehdashti F; Luo J; Homb A; Siegel BA; Bartlett NL
J Nucl Med; 2011 Mar; 52(3):386-92. PubMed ID: 21321279
[TBL] [Abstract][Full Text] [Related]
2. Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report.
Jurczak W; Bryk AH; Mensah P; Gałązka K; Trofimiuk-Müldner M; Wyrobek Ł; Sawiec A; Skotnicki AB
J Med Case Rep; 2016 May; 10(1):123. PubMed ID: 27178351
[TBL] [Abstract][Full Text] [Related]
3. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.
Vari F; Arpon D; Keane C; Hertzberg MS; Talaulikar D; Jain S; Cui Q; Han E; Tobin J; Bird R; Cross D; Hernandez A; Gould C; Birch S; Gandhi MK
Blood; 2018 Apr; 131(16):1809-1819. PubMed ID: 29449276
[TBL] [Abstract][Full Text] [Related]
4. Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis.
Terasawa T; Dahabreh IJ; Nihashi T
Oncologist; 2010; 15(7):750-9. PubMed ID: 20587551
[TBL] [Abstract][Full Text] [Related]
5. A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy.
Falchi L; Capello D; Palumbo B; Rauco A; Emili R; Cianciulli M; Pace R; Capparella V; Liberati F; Liberati AM
Eur J Haematol; 2007 Nov; 79(5):455-61. PubMed ID: 17908180
[TBL] [Abstract][Full Text] [Related]
6. A rare case of primary cardiac diffuse large B-cell lymphoma imaged with
Huang W; Zheng Z; Zhang Y; Qiu Y; Peng Y; Yang Q; Wang W; Kang L
Front Med (Lausanne); 2024; 11():1373773. PubMed ID: 38576712
[TBL] [Abstract][Full Text] [Related]
7. Orbital plasmablastic lymphoma with remission following chemotherapy.
Degnan AJ; Levy LM
J Radiol Case Rep; 2011; 5(2):1-7. PubMed ID: 22470775
[TBL] [Abstract][Full Text] [Related]
8. Current approaches to the treatment of non-Hodgkin's lymphoma.
Gisselbrecht C
Hematol Rep; 2011 Oct; 3(3s):e3. PubMed ID: 22586511
[TBL] [Abstract][Full Text] [Related]
9. Investigation of dose minimisation protocol for 18F-FDG PET-CT in the management of lymphoma postchemotherapy followup.
Sonoda LI; Sanghera B; Wong WL
ScientificWorldJournal; 2012; 2012():208135. PubMed ID: 22545010
[TBL] [Abstract][Full Text] [Related]
10. Interim FDG-PET improves treatment failure prediction in primary central nervous system Lymphoma: a LOC network prospective multicentric study.
Rozenblum L; Houillier C; Baptiste A; Soussain C; Edeline V; Naggara P; Soret M; Causse-Lemercier V; Willems L; Choquet S; Ursu R; Galanaud D; Belin L; Hoang-Xuan K; Kas A
Neuro Oncol; 2024 Feb; ():. PubMed ID: 38366824
[TBL] [Abstract][Full Text] [Related]
11. Primary Diffuse Large B-Cell Lymphoma of the Female Urethra: A Case Report and Review of the Literature.
Zeng H; Wang J; Deng R; Chen Z
Onco Targets Ther; 2020; 13():13015-13022. PubMed ID: 33376350
[TBL] [Abstract][Full Text] [Related]
12. The Dark Side of Activated Phosphoinositide 3-Kinase-δ Syndrome 2: A Story Rewritten through FDG-PET.
Catelli A; Nanni C; Mulè R; Zinzani PL; Sabattini E; Lanari M; Conti F
J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673479
[No Abstract] [Full Text] [Related]
13. Vincristine in Combination Therapy of Cancer: Emerging Trends in Clinics.
Škubník J; Pavlíčková VS; Ruml T; Rimpelová S
Biology (Basel); 2021 Aug; 10(9):. PubMed ID: 34571726
[TBL] [Abstract][Full Text] [Related]
14. Ruptured Baker Cyst on 18F-FDG PET/CT.
de Groot EM; van Amerongen MJ; Ploegmakers MJM; Zegers IHA; Arens AIJ
Clin Nucl Med; 2024 Apr; ():. PubMed ID: 38651792
[TBL] [Abstract][Full Text] [Related]
15. Endoscopic electrochemotherapy for esophageal cancer: a phase I clinical study.
Egeland C; Baeksgaard L; Johannesen HH; Löfgren J; Plaschke CC; Svendsen LB; Gehl J; Achiam MP
Endosc Int Open; 2018 Jun; 6(6):E727-E734. PubMed ID: 29868638
[TBL] [Abstract][Full Text] [Related]
16. [Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients].
Oriuchi N; Higuchi T; Endo K; Tsukamoto N; Matsuda H; Kuji I; Murakami K; Nakajima K
Kaku Igaku; 2009 Jun; 46(2):96-9. PubMed ID: 19637820
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Qiao W; Zhao J; Wang C; Wang T; Xing Y
Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
[TBL] [Abstract][Full Text] [Related]
18. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J
Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527
[TBL] [Abstract][Full Text] [Related]
19. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
